Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Executive Summary

Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.

Advertisement

Related Content

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m
Akero Thinks It Will Produce A Next-Wave Therapy For NASH With Former Amgen Compound
Learning From Human Cell Hijacking Masters: ENYO Pharma Takes Virus Tricks Into Drug Discovery
iTeos Says Adios To IDO And Eyes US IPO
£88m Series B For Syncona-backed Freeline To Advance Liver Gene Therapy Focus
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Venture Funding Deals, July – August 2016
Venture Funding Deals, June 2015

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel